SecBot SecBot
8-K ·Filed Feb 25, 2026

PEN

Penumbra Inc
MIXED
Impact 7/10
Horizonweeks Processed8mo ago SEC0001321732-26-000006
Actionable Insight ◆ Mixed

The strong financial performance suggests underlying business strength, but the pending acquisition by Boston Scientific creates significant uncertainty about the company's future as an independent entity and its ability to execute on its current trajectory.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$338.67
T+0 close · Feb 25, 2026 · via day close
Latest settled
−3.33%
T+60 · $327.38
Vs SPY
−10.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $338.67entry
  2. T+1 · 9mo ago +0.97%α +1.51% · $341.94
  3. T+5 · 9mo ago +0.28%α +1.38% · $339.61
  4. T+20 · 8mo ago −0.71%α +4.53% · $336.27
  5. T+60 · 6mo ago −3.33%α −10.28% · $327.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Penumbra reported strong 2025 full-year financial results with revenue of $1.4 billion (up 17.5% YoY) and net income of $177.7 million, driven by growth in both thrombectomy and embolization/access products. However, the company will not provide 2026 guidance due to its pending acquisition by Boston Scientific, which also led to the cancellation of its earnings call.

Key Financial Metrics

Revenue
$1.4B
+17.5% YoY
Adj. EPS
$3.84
GAAP: $4.52
Gross Margin
67.1%

Key Facts

  • Revenue of $1.4037 billion for full-year 2025, up 17.5% YoY
  • Net income of $177.7 million for full-year 2025, a significant improvement from $14 million in 2024
  • Income from operations increased to $189.2 million from $9.3 million in 2024
  • Company will not provide 2026 financial guidance due to pending acquisition by Boston Scientific
  • Company canceled its earnings call due to the pending acquisition

Financial Impact

Revenue increased by $209 million YoY, net income increased by $163.7 million YoY

revenuenet incomeoperating income

Segment Breakdown

SegmentRevenueGrowth
Thrombectomy$947.9M+16.2%
Embolization and Access$455.7M+20.2%

Risk Factors

  • Pending acquisition by Boston Scientific may not close as expected
  • Loss of operational independence and potential integration challenges
  • Uncertainty around future guidance and strategic direction

Market Snapshot

Exchange
NYSE

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (PEN), Batch item 10001321732-26-000006
Document: pen-20260225.htm0001321732-26-000006
Document: 0001321732-26-000006-index-headers.html0001321732-26-000006
Document: 0001321732-26-000006-index.html0001321732-26-000006
Document: 0001321732-26-000006.txt0001321732-26-000006
8-K Filing (PEN), Batch item 60001321732-26-000006
Document: pen-20260225.htm0001321732-26-000006
Document: 0001321732-26-000006-index-headers.html0001321732-26-000006
CONTEXT: Previous Earnings (2026-02-25)0001321732-26-000006

Track record

11 reports on PEN

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +1.63% at T+20 after the May 6, 2026 report. 1 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $321.46 Now $320.62 −0.26% settles Feb 8
  2. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $319.21 Now $320.62 +0.44% settles Feb 4
  3. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  4. Oct 29, 202618d ago Press Release Neutral 5/10 Entry $318.95 Now $320.62 +0.52% settles Jan 28
  5. Jul 30, 202615w ago Press Release Bearish 6/10 Entry $321.19 to $325.22 Now $320.62 +0.18% ▼ −1.25% +1.20% vs SPY
  6. May 7, 202627w ago 425 Bullish 7/10 Entry $324.65 to $323.02 Now $320.62 −1.24% ▼ −0.50% −4.34% vs SPY
  7. May 6, 202627w ago 8-K Bearish 6/10 Entry $324.65 to $323.02 Now $320.62 +1.24% ▲ +0.50% +4.34% vs SPY
  8. Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $326.48 to $319.49 Now $320.62 −1.79% ▼ −2.14% −5.25% vs SPY
  9. Apr 17, 202630w ago 425 Neutral 4/10 Entry $329.71 to $316.73 Now $320.62 −2.76% ▼ −3.94% −10.71% vs SPY
  10. Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $330.36 to $315.75 Now $320.62 −2.95% ▼ −4.42% −18.58% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026